WALTHAM, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin’s IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
“Working with Eleven Biotherapeutics to evaluate subjects in its Phase 3 study for the two ophthalmic indications was an exciting opportunity to demonstrate our unique ability to utilize IL-1 genetic patterns to help assess clinical response to a novel interleukin-1 receptor inhibitor in allergic conjunctivitis and dry eye,” said Ken Kornman, Chief Scientific Officer of Interleukin Genetics. “The IL-1 genetic pattern data showed that isunakinra treated subjects had a differential clinical response relative to vehicle control. These findings are consistent with previously published results showing that IL-1 genetic patterns identified individuals who were more likely to respond to another IL-1 blocking drug, anakinra, in rheumatoid arthritis.”
The Posters being presented by researchers from Eleven Biotherapeutics are:
“Phase 3 Multi-Center Trial Evaluating the Efficacy, Safety and Tolerability of Isunakinra (EBI-005) in Subjects with Moderate to Severe Allergic Conjunctivitis”
Date and Time: May 1, 2016, 8:30 a.m. to 10:15 a.m. (PT)
Abstract Number: 2307-C0121
Session: Allergic Conjunctivitis / Corneal Immunology and Infection
“A Phase 3 Multi-Center, Randomized Controlled Evaluation of the Efficacy, Safety and Tolerability of Isunakinra in Subjects with Moderate to Severe Dry Eye”
Date and Time: May 3, 2016, 8:30 a.m. to 10:15 a.m. (PT)
Abstract Number: 2874-A0083
Session: Dry Eye II
The utilization of the IL-1 genetic patterns may facilitate clinical development and commercial deployment of IL-1 inhibitors and drugs operating downstream of IL-1 since the IL-1 genetic patterns have been shown to differentiate individuals at the clinical level in terms of responses to inflammatory challenges or responses to IL-1 blocking drugs.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals and their healthcare providers to manage existing health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property, and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic test for periodontal disease and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements, including, but not limited to, statements that utilizing IL-1 genetic patterns to identify individuals who are more likely to respond to drugs that are intended to block IL-1 expression may facilitate the clinical development and commercial deployment of IL-1 inhibitors. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.
Source:Interleukin Genetics, Inc.